Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults

A multicomponent meningococcal serogroups ABCWY vaccine (MenABCWY) could provide broad protection against disease-causing meningococcal strains and simplify the immunisation schedule. 

Research

Geographical migration and fitness dynamics of Streptococcus pneumoniae

Streptococcus pneumoniae is a leading cause of pneumonia and meningitis worldwide. Many different serotypes co-circulate endemically in any one location. The extent and mechanisms of spread and vaccine-driven changes in fitness and antimicrobial resistance remain largely unquantified.

Research

Meningococcal Disease in the Post–COVID-19 Era: A Time to Prepare

The global invasive meningococcal disease (IMD) landscape changed considerably during the COVID-19 pandemic, as evidenced by decreased incidence rates due to COVID-19 mitigation measures, such as limited social contact, physical distancing, mask wearing, and hand washing. Vaccination rates were also lower during the pandemic relative to pre-pandemic levels.

Research

Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine

We have previously reported the safety and immunogenicity four weeks after two doses of the Clover COVID-19 vaccine candidate, SCB-2019, a stabilized pre-fusion form of the SARS-CoV-2 S-protein (S-trimer). We now report persistence of antibodies up to 6 months after vaccination, and cross-neutralization titers against three Variants of Concern.

Research

S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine

Based on descriptive analyses of this small study, S. aureus 3-antigen vaccine vaccination did not impact S. aureus acquisition or carriage

Research

Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect.

Recurrent severe asthma exacerbations are associated with decreased lung growth or accelerated loss of long function and add substantially to cost and morbidity

Research

Efficacy and safety of influenza vaccination during pregnancy: realizing the potential of maternal influenza immunization

Pregnant women are at higher risk of severe complications following influenza infection compared to the general population. Influenza vaccination during pregnancy can offer direct protection to pregnant women and passive immunity to infants up to 6 months of age via maternal antibodies. Pregnant women are a high priority group for influenza immunization.

Research

Excess respiratory mortality and hospitalizations associated with influenza in Australia, 2007-2015

Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.

Research

The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology

Our review highlights similarities and differences in the application of the test-negative design that deserve further examination

Research

Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in Fiji

Indigenous iTaukei had greater frequency and intensity of contact compared with Fijians of Indian Descent